Bristol’s Oral TYK2 Inhibitor Beats Amgen’s Otezla In Phase III
Top-Line Psoriasis Efficacy Bested Placebo; Safety Similar To Phase II
Bristol Myers Squibb released no detailed data from the first Phase III trial of deucravacitinib (BMS-986165) in psoriasis but said it achieved superiority to placebo and Otezla with safety similar to Phase II.
You may also be interested in...
Deucravacitinib is an oral drug in development for a wide range of autoimmune conditions, including psoriasis and psoriatic arthritis.
Patients’ COVID-19 anxiety continues to keep them from seeking treatments for psoriasis, migraine and even cancer, Amgen said, blaming the pandemic for much of its 4% decline in first quarter revenue.
The company has not even filed the TYK2 inhibitor deucravacitinib for psoriasis, but Bristol will be a new player in a category dominated by entrenched rivals.